Stocks and Investing
by (remove) : Andrew Galler
RSS • JSON • XML • CSV
Stocks and Investing
by (remove) : Andrew Galler
RSS • JSON • XML • CSV

Andrew Galler Maintained (ARWR) at Hold with Decreased Target to $37 on, Nov 29th, 2022


Published on 2024-10-28 00:21:45 - WOPRAI, Andrew Galler
  Print publication without navigation


Andrew Galler of Morgan Stanley, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Decreased Target from $41 to $37 on, Nov 29th, 2022.

Andrew has made no other calls on ARWR in the last 4 months.



There are 2 other peers that have a rating on ARWR. Out of the 2 peers that are also analyzing ARWR, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Andrew

  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $64 on, Thursday, November 10th, 2022
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $65 on, Monday, August 8th, 2022
Contributing Sources